BriaCell Therapeutics (FRA:8BT) Total Equity : €-2.48 Mil (As of Jul. 2024)

View and export this data going back to 2015. Start your Free Trial

What is BriaCell Therapeutics Total Equity?

BriaCell Therapeutics's total equity for the quarter that ended in Jul. 2024 was €-2.48 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

BriaCell Therapeutics Total Equity Historical Data

The historical data trend for BriaCell Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Total Equity Chart

BriaCell Therapeutics Annual Data

Trend

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Jul24

Total Equity

Get a 7-Day Free Trial

-3.13

23.41

10.15

-3.41

-2.48

BriaCell Therapeutics Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
Total Equity	Get a 7-Day Free Trial															-3.41	2.38	-7.64	-5.81	-2.48

BriaCell Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

BriaCell Therapeutics's Total Equity for the fiscal year that ended in Jul. 2024 is calculated as

Total Equity	=	Total Assets(Q: Jul. 2024 )	-	Total Liabilities(Q: Jul. 2024 )
	=	5.414	-	7.89
	=	-2.48

BriaCell Therapeutics's Total Equity for the quarter that ended in Jul. 2024 is calculated as

Total Equity	=	Total Assets(Q: Jul. 2024 )	-	Total Liabilities(Q: Jul. 2024 )
	=	5.414	-	7.89
	=	-2.48

BriaCell Therapeutics Total Equity Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

BriaCell Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (FRA:8BT) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

BCTX:USA 8BT:Germany BCT:Canada

Address

235 - 15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1

Website

https://www.briacell.com

BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

BriaCell Therapeutics Headlines

No Headlines